follow brist-en
bottom line numer convers investor today
also chanc follow investor relat bristol follow
seri press releas bristol releas morn relat
opdivo otezla time expect celgen deal close
provid updat thought common question
receiv
price month
 close
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
bristol-my squibb compani bm engag discoveri
develop licens manufactur market distribut
sale pharmaceut product global basi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
opdivo/i-o eliqui yervoy compar current base case
assumpt blue sky valuat base dcf driven
wacc termin valu
grey sky valuat base lower sale opdivo/i-
eliqui yervoy compar current base case assumpt
grey sky valuat base dcf driven wacc
 close
updat bristol
would ftc concern bristol buy celgen one
first question morn expect bristol would need
divest otezla order complet celgen deal base interpret
situat believ ftc concern may relat newco
lead oral drug moderate-sever psoriasi well one
compel de-risk oral pipelin option oppos broader concern
compani two product psoriasi especi import
relat next question
may interest abl buy otezla assum correct
ftc concern relat overlap within market oral drug
moderate-sever psoriasi would number compani
inject psoriasi drug believ would interest supplement
portfolio otezla addit compani broader dermatolog
market may see valu ad oral psoriasi drug otezla final
could compani may look otezla financi perspect
seek acquir product near-term sale earn impact even
less strateg overlap coverag alon could see compani
 lilli potenti interest acquir otezla
convers bristol made clear expect signific interest
asset overal would surpris us number compani look
acquir high margin blockbust product still sever year growth
expect ahead
reason price otezla busi heard wide rang
answer question proprietari pharmavalu databas suggest npv
asset given bristol forc seller situat would
surpris obtain signific premium asset rang possibl
buyer suggest us like need sell signific discount
either expect neg tax impact sale yet attempt
quantifi overal think impact divestitur
materi context deal size time loss otezla
dilut newco near-term sale earn outlook place addit pressur
remain market pipelin asset drive valu deal
would divest otezla delay deal close end
extens deal close timelin end
rais eyebrow investor spoke tend agre
broad timelin order compani run process buy busi
otezla size also allow time ftc review approv agreement
would bristol divest otezla instead investor
ask bristol would decid divest success commerci product favor
pipelin product could face clinic regulatori commerci setback one
hand believ compani necessarili much choic
situat believ ftc tend prefer less riski commerci product
divest hand believ hold onto make sens
given emerg profil asset longer life cycl front
anyth uniqu manufactur process otezla
complic would transit otezla manufactur new provid
believ celgen manufactur otezla in-hous third parti
addit small molecul appear anyth uniqu
manufactur otezla believ would overli complic transit
product whatev compani end buy
make opdivo failur much impact
stock today think major sell-off bristol share today due
updat around otezla deal close timelin expect data
hepatocellular carcinoma liver cancer somewhat limit especi
merck releas neg data hepatocellular carcinoma earlier year
trial
data impact expect upcom checkmate-
data top-line result part trial still
expect summer like next key catalyst bristol share
believ expect alreadi somewhat limit think
real direct read-through although anoth
bristol studi result data least somewhat disappoint
like increas gener caution investor
expect next asset cvr remind cvr
tie fda approv ozanimod decemb liso-cel also decemb
march next key event asset
top-line data fda submiss liso-cel fda
action date ozanimod march
think bristol level ultim view bristol
chang materi today continu see potenti upsid stock
pure valuat perspect remain neutral rate stock wait
upcom data releas regulatori updat along sign progress close
deal work complic multi-year integr process
unfortun deal close push month like limit interest
new investor may stock near-term time could see
addit interest investor focus potenti long-term valu opportun
figur oral pipelin candid treat psoriasi
psoriasi
mechan action
nf-kappa nuclear factor kappa-light-chain-enhanc activ cell
compani mention price
